The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy
Open accessAbstract
The Wnt/β-catenin signaling pathway is activated in breast cancer, a leading cause of cancer mortality in women. Because mutations in the key intracellular components of this pathway are rare, identifying the molecular mechanisms of aberrant Wnt activation in breast cancer is critical for development of pathway-targeted therapy. Here, we show that expression of the Wnt signaling coreceptor LRP6 is up-regulated in a subpopulation of human breast cancers. LRP6 silencing in breast cancer cells reduces Wnt signaling, cell proliferation, and in vivo tumor growth. In vivo administration of an LRP6 antagonist, Mesd, markedly suppressed growth of MMTV-Wnt1 tumors without causing undesirable side effects. These results demonstrate that Wnt activation at the cell surface contributes to breast cancer tumorigenesis. Together, our studies highlight LRP6 as a potential therapeutic target in breast cancer, and introduce Mesd as a promising antitumor agent for treating breast cancer subtypes with Wnt activation at the cell surface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H.-J., Glass, D. A., Hartmann, C., Li, L., Hwang, T.-H., Brayton, C. F., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201089 · Cited by 1,086 · cited 1×
“LRP6 knockout in mice is embryonic lethal, whereas Lrp5-deficient mice are viable and fertile (32, 33).”
BackgroundMesd Encodes an LRP5/6 Chaperone Essential for Specification of Mouse Embryonic Polarity
Hsieh, J.-C., Lee, L., Zhang, L., Wefer, S., Brown, K., DeRossi, C., Wines, M. E., Rosenquist, T., & Holdener, B. C. (2003) · Cell · doi:10.1016/s0092-8674(03)00045-x · Cited by 237
Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding
Li, Y., Chen, J., Lu, W., McCormick, L. M., Wang, J., & Bu, G. (2005) · Journal of Cell Science · doi:10.1242/jcs.02651 · Cited by 53
Self-citation
Cited by
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
G protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Lu, D., Choi, M. Y., Yu, J., Castro, J. E., Kipps, T. J., & Carson, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110431108 · Cited by 395
The role of intratumoral and systemic IL-6 in breast cancer
Dethlefsen, C., Højfeldt, G., & Hojman, P. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2488-z · Cited by 363
Metadata
- Authors
- Liu, C.-C., Prior, J., Piwnica-Worms, D., & Bu, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-03
- Volume
- 107
- Issue
- 11
- Pages
- 5136-5141
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2074839194
- Cited by
- 207
- References
- 3
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. https://app.cochat.ai/papers/10.1073/pnas.0911220107
- The paper
- Liu, C.-C., Prior, J., Piwnica-Worms, D., & Bu, G. (2010). LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0911220107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.